TURKISH JOURNAL OF ONCOLOGY 2024 , Vol 39 , Num 2
Radiotherapy with a Carboplatin/Paclitaxel Regimen in Patients with Non-Small-Cell Lung Cancer: Experience at Ondokuz Mayıs University
Alparslan SERARSLAN1,Nilgün ÖZBEK OKUMUŞ1,Rana Elif YILDIZ1,Bilge GÜRSEL1,Deniz MEYDAN1
1Department of Radiation Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun-Türkiye DOI : 10.5505/tjo.2023.4204 OBJECTIVE
We investigated the outcomes of radiotherapy (RT) combined with systemic chemotherapy (CHT) including carboplatin and paclitaxel in patients with locally advanced non-small-cell lung cancer.

METHODS
This retrospective study included 105 patients. Treatment involved concurrent carboplatin and paclitaxel with RT administered weekly followed by two cycles of consolidation carboplatin and paclitaxel administered triweekly.

RESULTS
Comorbid disease was present in 46 (48.6%) patients. At least four cycles of CHT in the concurrent phase and both cycles of CHT in the consolidation phase were able to be administered to 92.3% and 45.4% of patients, respectively. The most common type of toxicity in the entire treatment protocol was hematological toxicity (34.8%). The objective response rate was 71.4%. Overall, recurrence was found in 71 (67.6%) patients. The most common type of recurrence was distant metastasis, which occurred in 47 (66.2%) patients. The median progression-free survival was 14 months. The 1, 2, and 3-year progressionfree survival rates were 59%, 30%, and 26%, respectively. The median overall survival was 27 months. The 1, 2, and 3-year overall survival rates were 81%, 57%, and 34%, respectively.

CONCLUSION
The survival outcomes in this study closely match those reported in the literature. This is notable because our study included a higher proportion of patients with additional health conditions and fewer concurrent CHT cycles during RT compared to randomized studies. These findings prompt us to consider what the ideal number of concurrent CHT cycles should be when using modern involved-field RT techniques after accurate disease staging. Keywords : Carboplatin; chemotherapy; concurrent radiochemotherapy; non-small-cell lung cancer; paclitaxel; radiotherapy